Quarterly report pursuant to Section 13 or 15(d)

Equity Method Investment

Equity Method Investment
3 Months Ended
Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]  



As of March 31, 2020 and December 31, 2019, the equity method investment amounted to $466,014 and $483,101, respectively. The investment represents the Company's subsidiary, Avalon Shanghai's interest in Epicon Biotech Co., Ltd. ("Epicon"). Epicon was incorporated on August 14, 2018 in PRC. Avalon Shanghai and the other unrelated company, Jiangsu Unicorn Biological Technology Co., Ltd. ("Unicorn"), accounted for 40% and 60% of the total ownership, respectively. Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. The Company treats the equity investment in the consolidated financial statements under the equity method. Under the equity method, the investment is initially recorded at cost, adjusted for any excess of the Company's share of the incorporated-date fair values of the investee's identifiable net assets over the cost of the investment (if any). Thereafter, the investment is adjusted for the post incorporation change in the Company's share of the investee's net assets and any impairment loss relating to the investment.


For the three months ended March 31, 2020 and 2019, the Company's share of Epicon's net loss was $9,084 and $12,743, respectively, which was included in loss from equity-method investment in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. Activity recorded for the Company's equity method investment in Epicon is summarized in the following table:


Equity investment carrying amount at January 1, 2020   $ 483,101  
Epicon's net loss attributable to the Company     (9,084 )
Foreign currency fluctuation     (8,003 )
Equity investment carrying amount at March 31, 2020   $ 466,014  


The tables below present the summarized financial information, as provided to the Company by the investee, for the unconsolidated company:


    March 31,
    December 31,
Current assets   $ 32,865     $ 77,272  
Noncurrent assets     264,439       247,590  
Current liabilities     619       324  
Noncurrent liabilities     -       -  
Equity     296,685       324,538  


    For the Three Months Ended
March 31,
    2020     2019  
Net revenue   $ -     $ -  
Gross profit     -       -  
Loss from operation     22,711       31,856  
Net loss     22,711       31,856